NatalieSCallanderMD

Oncology • Madison, WI

Hematologic Oncology

Associate Professor, Medicine, University of Wisconsin Medical School

Join to view full profile

Dr. Callander is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Callander's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1988 - Present
WI State Medical License 2004 - 2025
TX State Medical License 1995 - 2024
GA State Medical License 1989 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2012 Dec 19
Completed
Phase 1
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jul 23
Completed
Phase 1
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
Selinexor and Backbone Treatments of Multiple Myeloma Patients Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 26
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka
Blood. 2024-12-05
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.
Timothy Schmidt, Zhubin Gahvari, Natalie S Callander
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke
Cancer. 2024-08-01

Abstracts/Posters

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoi...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

COVID-19 Vaccines Are Safe for People with Cancer, Researchers SayFebruary 7th, 2022
COVID mRNA Vaccine Equally Safe for People with CancerFebruary 7th, 2022
Multiple Myeloma: Choosing Your PathDecember 18th, 2020
Join now to see all